Project Grant R24AI192252
Award Date
7/21/25
Completion Date
6/30/30
Dollars Obligated
$1.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $170,000 research project by Prokaryotics Incorporated to develop novel antifungal therapeutics. The goal is to perform structural biology studies on the GPI ethanolamine phosphate transferase enzyme MCD4, which is a promising target for new antifungal drug candidates. The research aims to obtain...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) provides $1,172,336.00 to the University of Massachusetts Medical School over a 5-year period starting on August 19, 2024. The goal of the research is to investigate how distinct age-associated B cell subsets can protect the aged from influenza. Specifically, the project will determine the potential of different...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, has awarded a $300,156 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Intact Genomics Inc., a minority-owned small business. The funding will support research to identify new antifungal compounds with novel mechanisms of action from filamentous fungi. The key objectives are to demonstrate the use of Aspergillus nidulans as a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $249,749 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The University of Iowa. The grant supports research to develop a new approach for analyzing the transcriptional control of virulence in the fungal pathogen Aspergillus fumigatus, a leading cause of life-threatening infections in immunocompromised patients. The research aims to express a nanobody-E3 ligase fusion protein...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $782,178 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation for the State University of New York, doing business as Stony Brook University. The grant supports research to develop novel antifungal inhibitors targeting the sterylglucosidase enzymes SGL1 and SGLA, which are essential for the pathogenicity of the fungal pathogens Cryptococcus neoformans and...
This federal Project Grant award, valued at $472,210.00 and effective June 23, 2025 through May 31, 2027, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by the University of Massachusetts Medical School to investigate the spatiotemporal relationship between CD4+ T resident memory cells and neutrophil recruitment in the lungs during pneumonia in experienced...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,977,446 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University on August 1, 2025. This 5-year award, scheduled for completion by June 30, 2030, aims to establish a Center of Excellence in Translational Research focused on rapidly developing new drugs and diagnostics to combat drug-resistant fungal infections. The key products and services to be...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $750,815 to the University of Maryland, Baltimore to conduct research on developing novel therapeutic approaches to treat mucormycosis, a deadly invasive fungal infection. The key research objectives are: Examining the role of the host cell hypoxia-response pathway and the ANGPTL4 protein in the pathogenesis of mucormycosis, and exploring the...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...